A novel nanoparticle delivery system for in vivo targeting of the sciatic nerve: Impact on regeneration

Nanomedicine

Volumn 7, Issue 8, 2012, Pages 1167-1180

  Gonçalves, Nádia Pereira ^a,b   Oliveira, Hugo ^b,c   Pêgo, Ana Paula ^c   Saraiva, Maria João ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

Author keywords

chitosan; drug delivery system; heparin; nanomedicine; nanoparticles; peripheral nerve regeneration; sciatic nerve

Indexed keywords

CHIMARIN; CHITOSAN; GROWTH FACTOR; HEPARIN; NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; EXTRACELLULAR MATRIX; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INFLAMMATION; MOUSE; NANOMEDICINE; NANOPARTICLE DELIVERY SYSTEM; NERVE CRUSH; NERVE FIBER REGENERATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SAFETY; SCIATIC NERVE INJURY; SENSORIMOTOR FUNCTION; ZETA POTENTIAL;

ANIMALS; CHITOSAN; DRUG DELIVERY SYSTEMS; HEPARIN; INFLAMMATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; NANOPARTICLES; NERVE REGENERATION; SCIATIC NERVE; SWINE;

EID: 84868111412     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.11.188     Document Type: Article

References (46)

1. Rodriguez FJ, Valero-Cabre A, Navarro X. Regeneration and functional recovery following peripheral nerve injury. Drug Discov. Today 1(2), 177-185 (2004). (Pubitemid 41123769)
2. Apfel SC. Neurotrophic factors in peripheral neuropathies: therapeutic implications. Brain Pathol. 9(2), 393-413 (1999). (Pubitemid 29157723)
3. Battiston B, Geuna S, Ferrero M, Tos P. Nerve repair by means of tubulization: literature review and personal clinical experience comparing biological and synthetic conduits for sensory nerve repair. Microsurgery 25, 258-267 (2005). (Pubitemid 40980457)
4. Madduri S, Gander B. Schwann cell delivery of neurotrophic factors for peripheral nerve regeneration. J. Peripher. Nerv. Syst. 15, 93-103 (2010).
5. Kas HS. Chitosan: properties, preparations and application to microparticulate systems. J. Microencap. 14, 689-711 (1997). (Pubitemid 27483088)
6. Aimin C, Chunlin H, Juliang B, Tinyin Z, Zhichao D. Antibiotic loaded chitosan bar. An in vitro, in vivo study of a possible treatment for osteomyelitis. Clin. Orthop. 366, 239-247 (1999). (Pubitemid 29439361)
7. Nunthanid J, Puttipipatkhachorn S, Yamamoto K, Peck GE. Physical properties and molecular behavior of chitosan films. Drug Dev. Ind. Pharm. 27, 143-157 (2001). (Pubitemid 32207371)
8. Singla AK, Chawala M. Chitosan: some pharmaceutical and biological aspects-an update. J. Pharm. Pharmacol. 53, 67-147 (2001).
9. Liu Z, Jiao Y, Liu F, Zhang Z. Heparin/ chitosan nanoparticle carriers prepared by polyelectrolyte complexation. J. Biomed. Mater. Res. A 83(3), 806-812 (2007). (Pubitemid 350086307)
10. Chavez-Delgado ME, Gomes-Pinedo U, Feria-Velasco A et al. Ultrastructural analysis of guided nerve regeneration using progesterone-and pregnenolone-loaded chitosan prostheses. J. Biomed. Matter. Res. B Apply Biomater. 74(1), 589-600 (2005). (Pubitemid 40917730)
11. Li X, Wang W, Wei G, Wang G, Zhang W, Ma X. Immunophilin FK506 loaded in chitosan guides promotes peripheral nerve regeneration. Biotechnol. Lett. 32(9), 1333-1337 (2010).
12. Lin YH, Chang CH, Wu YS et al. Development of pH-responsive chitosan/ heparin nanoparticles for stomach-specific anti-Helicobacter pylori therapy. Biomaterials 30, 3332-3342 (2009).
13. Sakiyama-Elbert SE, Hubbell JA. Development of fibrin derivatives for controlled release of heparin-binding growth factors. J. Control Release 65(3), 389-402 (2000). (Pubitemid 30122941)
14. Lee AC, Yu VM, Lowe JB et al. Controlled release of nerve growth factor enhances sciatic nerve regeneration. Exp. Neurol. 184(1), 295-303 (2003). (Pubitemid 37444039)
15. Ohta M, Suzuki Y, Chou H et al. Novel heparin/alginate gel combined with basic fibroblast growth factor promotes nerve regeneration in rat sciatic nerve. J. Biomed. Mater. Res. A 71(4), 661-668 (2004). (Pubitemid 39578680)
16. Chu H, Johnson NR, Mason NS, Wang YA. A [polycation:heparin] complex releases growth factors with enhanced bioactivity. J. Control Release 150(2), 157-163 (2010).
17. Chau CH, Shum DK, Chan YS, So KF. Heparan sulphates upregulate regeneration of transected sciatic nerves of adult guinea-pigs. Eur. J. Neurosci. 11(6), 1914-1926 (1999). (Pubitemid 29240556)
18. Dow KE, Riopelle RJ, Kisilevsky R. Domains of neuronal heparin sulphate proteoglycans involved in neurite growth on laminin. Cell Tissue Res. 265, 345-351 (1991).
19. Gorio A, Vergani L, Ferro L, Prino G, DiGiulio AM. Glycosaminoglycans in nerve injury: II. Effects on transganglionic degeneration and on the expression of neurotrophic factors. J. Neurosci. Res. 46(5), 572-580 (1996). (Pubitemid 26404650)
20. Gorio A, Lesma E, Vergani L, DiGiulio AM. Glycosaminoglycan supplementation promotes nerve regeneration and muscle reinnervation. Eur. J. Neurosci. 9(8), 1748-1753 (1997). (Pubitemid 27348333)
21. Boddohi S, Moore N, Johnson PA, Kipper MJ. Polysaccharide-based polyelectrolyte complex nanoparticles from chitosan, heparin and hyaluronan. Biomacromolecules 10, 1402-1409 (2009).
22. Moreira C, Oliveira H, Pires LR, Simões S, Barbosa MA, Pêgo AP. Improving chitosan-mediated gene transfer by the introduction of intracellular buffering moieties into the chitosan backbone. Acta Biomaterialia 5, 2995-3006 (2009).
23. de Medinaceli L, Freed WJ, Wyatt RJ. An index of the functional condition of rat sciatic nerve based on measurements made from walking tracks. Exp. Neurol. 77 (3), 634-643 (1982). (Pubitemid 12011176)
24. Bain JR, Mackinnon SE, Hunter DA. Functional evaluation of complete sciatic, peroneal, and posterior tibial nerve lesions in the rat. Plast. Reconstr. Surg. 83, 129-136 (1989). (Pubitemid 19040670)
25. Hare GMT, Evans PJ, Mackinnon SE et al. Walking track analysis: a long-term assessment of peripheral nerve recovery. Plast. Reconstr. Surg. 89, 251-258 (1992).
26. Moghimi SM, Hunter CA, Murray JC. Nanomedicine: current status and future prospects. FASEB J. 19, 311-330 (2005). (Pubitemid 40316520)
27. Xu C, Inokuma MS, Denham J et al. Feeder-free growth of undifferentiated human embryonic stem cells. Nat. Biotechnol. 19, 971-974 (2001). (Pubitemid 32947578)
28. Xu XM, Guenard V, Kleitman N, Bunge MB. Axonal regeneration into Schwann cell-seeded guidance channels grafted into transected adult rat spinal cord. J. Comp. Neurol. 351(1), 145-160 (1994).
29. Chen MC, Wong HS, Lin KJ et al. The characteristics, biodistribution and bioavailability of a chitosan-based nanoparticulate system for the oral delivery of heparin. Biomaterials 30, 6629-6637 (2009).
30. Oyarzun-Ampuero FA, Brea J, Loza MI, Torres D, Alonso MJ. Chitosan-hyaluronic acid nanoparticles loaded with heparin for the treatment of asthma. Int. J. Pharm. 381(2), 122-129 (2009).
31. Mao HQ, Roy K, Troung-le VL et al. Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J. Control. Release 70, 399-421 (2001). (Pubitemid 32155463)
32. Koping-Hoggard M, Tubulekas I, Guan H et al. Chitosan as a non-viral gene delivery system. Structure-property relationships and characteristics compared with polyethylenimine in vitro and after lung administration in vivo. Gene Ther. 8(14), 1108-1121 (2001). (Pubitemid 32962708)
33. Huang M, Ma Z, Khor E, Lim LY. Uptake of FITC-chitosan nanoparticles by A549 cells. Pharm. Res. 19, 1488-1494 (2002). (Pubitemid 35266553)
34. Fang N, Chan V, Mao HQ, Leong KW. Interactions of phospholipid bilayer with chitosan: effect of molecular weight and pH. Biomacromolecules 2, 1161-1168 (2001). (Pubitemid 34026893)
35. Thanou M, Verhoef JC, Junginger HE. Chitosan and its derivatives as intestinal absorption enhancers. Adv. Drug Deliv. Rev. 50, 91-101 (2001).
36. Artursson P, Lindmark T, Davis SS, Illum L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm. Res. 11, 1358-1361 (1994). (Pubitemid 24287420)
37. Bowman K, Leong KW. Chitosan nanoparticles for oral drug and gene delivery. Int. J. Nanomed. 1(2), 117-128 (2006).
38. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro-and nanoparticles in drug delivery. J. Control. Release 100, 5-28 (2004). (Pubitemid 39445982)
39. Mittnacht U, Hartmann H, Hein S et al Chitosan/siRNA nanoparticles biofunctionalize nerve implants and enable neurite outgrowth. Nano Lett. 10(10), 3933-3939 (2010).
40. Oliveira H, Pires LR, Fernandez R, Martins MC, Simões S, Pêgo AP. Chitosan-based gene delivery vectors targeted to the peripheral nervous system. J. Biomed. Mater. Res. A 95(3), 801-810 (2010).
41. Kofuji K, Ito T, Murata Y, Kawashima S. Effect of chondroitin sulphate on the biodegradation and drug release of chitosan gel beads in subcutaneous air pouches of mice. Biol. Pharm. Bull. 25(2), 268-271 (2002). (Pubitemid 39592120)
42. Pires LR, Oliveira H, Barrias CC et al. Imidazole-grafted chitosan-mediated gene delivery: in vitro study on transfection, intracellular trafficking and degradation. Nanomedicine (Lond.) 6(9), 1499-1512 (2011).
43. Baldrick P. The safety of chitosan as a pharmaceutical excipient. Regul. Toxicol. Pharmacol. 56(3), 290-299 (2010).
44. Pavinatto FJ, Pavinatto A, Caseli L et al. Interaction of chitosan with cell membrane models at the air-water interface. Biomacromolecules 8, 1633-1640 (2007). (Pubitemid 46865138)
45. Sorokin L. The impact of the extracellular matrix on inflammation. Nat. Rev. Immunol. 10(10), 712-723 (2010).
46. Roghani M, Mansukhani A, Dell'Era P et al. Heparin increases the affinity of basic fibroblast growth factor for its receptor but is not required for binding. J. Biol. Chem. 269(6), 3976-3984 (1994). (Pubitemid 24237743)